Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17872738 | 1.00 | KDM1A (0.48) | KDM1AMAOAMAOBRCOR1DRD2 | |
| SCHEMBL17872734 | 1.00 | KDM1A (0.48) | KDM1AMAOAMAOBRCOR1DRD2 | |
| SCHEMBL1608039 | 0.79 | KDM1A (0.40) | KDM1AMAOBRCOR1MEN1KMT2A | |
| SCHEMBL1539148 | 0.79 | KDM1A (0.40) | KDM1AMAOBRCOR1MEN1KMT2A | |
| SCHEMBL10226674 | 0.79 | KDM1A (0.40) | KDM1AMAOBRCOR1MEN1KMT2A | |
| SCHEMBL20187414 | 0.75 | MAOA (0.53) | KDM1AMAOAMAOBDRD2SLC6A3 | |
| SCHEMBL668905 | 0.75 | SLC6A4 (0.47) | KDM1AMAOAMAOBDRD2SLC6A3 | |
| SCHEMBL27288645 | 0.75 | KDM1A (0.44) | KDM1AMAOAMAOBRCOR1DRD2 | |
| Hydrochloric Acid SCHEMBL1919156 | 0.73 | SLC6A4 (0.45) | KDM1AMAOAMAOBDRD2SLC6A3 | |
| SCHEMBL8478708 | 0.71 | SLC6A4 (0.53) | SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| US-10336702-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2019-07-02 | — | — | US | disclosed |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2018-02-01 | — | — | US | disclosed |
| EP-3240784-A2 | INHIBITORS OF AKT KINASE | BerGenBio ASA (NO) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016102672-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336702-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | KDM1A 4460/4885MAOA 895/4885MAOB 589/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | KDM1A 4419/4885MAOA 901/4885MAOB 633/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | KDM1A 4419/4885MAOA 901/4885MAOB 633/4885 |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | UGT2B7, CYP3A5, UGT1A1 | KDM1A 4460/4885MAOA 895/4885MAOB 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.